Johnson & Johnson Litigation Settlement, Expense
Johnson & Johnson (JNJ) reported Litigation Settlement, Expense of $264.00 million for the 3-month period ending 2019-12-29, per its 10-K filed 2020-02-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LitigationSettlementExpense · last filed 2020-02-18
- Johnson & Johnson litigation settlement, expense for the quarter ending 2019-12-29 was $264.00M, a 79.50% decline year-over-year.
- Johnson & Johnson litigation settlement, expense for the quarter ending 2019-09-29 was $4.00B.
- Johnson & Johnson litigation settlement, expense for the quarter ending 2019-06-30 was $409.00M, a 41.82% decline year-over-year.
- Johnson & Johnson litigation settlement, expense for the quarter ending 2019-03-31 was $423.00M.
- Johnson & Johnson litigation settlement, expense for fiscal 2016 was $141.00M, a 88.75% decline from fiscal 2014.
- Johnson & Johnson litigation settlement, expense for fiscal 2014 was $1.25B, a 44.95% decline from fiscal 2013.
- Johnson & Johnson litigation settlement, expense for fiscal 2013 was $2.28B, a 86.86% increase from fiscal 2012.
- Johnson & Johnson litigation settlement, expense for fiscal 2012 was $1.22B, a 63.20% decline from fiscal 2012.
| Period end | Litigation Settlement, Expense 3 month | Litigation Settlement, Expense 6 month | Litigation Settlement, Expense 9 month | Litigation Settlement, Expense 12 month | Litigation Settlement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-29 | $264.00M 10-K · filed 2020-02-18 | $4.26B derived: sum of 2 quarters · filed 2020-02-18 | $4.67B derived: sum of 3 quarters · filed 2020-02-18 | $5.10B derived: sum of 4 quarters · filed 2020-02-18 | |
| 2019-09-29 | $4.00B 10-K · filed 2020-02-18 | $4.41B derived: sum of 2 quarters · filed 2020-02-18 | $4.83B derived: sum of 3 quarters · filed 2020-02-18 | $6.12B derived: sum of 4 quarters · filed 2020-02-18 | |
| 2019-06-30 | $409.00M 10-K · filed 2020-02-18 | $832.00M derived: sum of 2 quarters · filed 2020-02-18 | $2.12B derived: sum of 3 quarters · filed 2020-02-18 | ||
| 2019-03-31 | $423.00M 10-K · filed 2020-02-18 | $1.71B derived: sum of 2 quarters · filed 2020-02-18 | |||
| 2018-12-30 | $1.29B 10-K · filed 2020-02-18 | ||||
| 2018-07-01 | $703.00M 10-K · filed 2020-02-18 | ||||
| 2017-12-31 | $645.00M 10-K · filed 2019-02-20 | $763.00M derived: sum of 2 quarters · filed 2019-02-20 | $1.26B derived: sum of 3 quarters · filed 2019-02-20 | ||
| 2017-10-01 | $118.00M 10-K · filed 2019-02-20 | $611.00M derived: sum of 2 quarters · filed 2019-02-20 | |||
| 2017-07-02 | $493.00M 10-K · filed 2019-02-20 | ||||
| 2017-01-01 | $96.00M 10-K · filed 2018-02-21 | $151.00M derived: sum of 2 quarters · filed 2018-02-21 | $751.00M derived: sum of 3 quarters · filed 2018-02-21 | $817.00M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-10-02 | $55.00M 10-K · filed 2018-02-21 | $655.00M derived: sum of 2 quarters · filed 2018-02-21 | $721.00M derived: sum of 3 quarters · filed 2018-02-21 | ||
| 2016-07-03 | $600.00M 10-K · filed 2018-02-21 | $666.00M derived: sum of 2 quarters · filed 2018-02-21 | |||
| 2016-04-03 | $66.00M 10-K · filed 2018-02-21 | ||||
| 2016-01-03 | $141.00M 10-K · filed 2018-02-21 | ||||
| 2015-09-27 | $409.00M 10-K · filed 2017-02-27 | $543.00M derived: sum of 2 quarters · filed 2017-02-27 | |||
| 2015-06-28 | $134.00M 10-K · filed 2017-02-27 | ||||
| 2014-12-28 | $692.00M 10-K · filed 2016-02-24 | $977.00M derived: sum of 2 quarters · filed 2016-02-24 | $1.25B derived: sum of 3 quarters · filed 2016-02-24 | $1.25B 10-K · filed 2017-02-27 | |
| 2014-09-28 | $285.00M 10-K · filed 2016-02-24 | $561.00M derived: sum of 2 quarters · filed 2016-02-24 | |||
| 2014-06-29 | $276.00M 10-K · filed 2016-02-24 | ||||
| 2013-12-29 | $506.00M 10-K · filed 2015-02-24 | $1.38B derived: sum of 2 quarters · filed 2015-02-24 | $1.75B derived: sum of 3 quarters · filed 2015-02-24 | $2.28B 10-K · filed 2016-02-24 | |
| 2013-09-29 | $872.00M 10-K · filed 2015-02-24 | $1.25B derived: sum of 2 quarters · filed 2015-02-24 | $1.78B derived: sum of 3 quarters · filed 2015-02-24 | $2.92B derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-06-30 | $375.00M 10-K · filed 2015-02-24 | $904.00M derived: sum of 2 quarters · filed 2015-02-24 | $2.05B derived: sum of 3 quarters · filed 2015-02-24 | $2.05B derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-03-31 | $529.00M 10-K · filed 2015-02-24 | $1.67B derived: sum of 2 quarters · filed 2015-02-24 | $1.67B derived: sum of 3 quarters · filed 2015-02-24 | $1.67B derived: sum of 4 quarters · filed 2015-02-24 | |
| 2012-12-30 | $1.15B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $1.15B derived: sum of 2 quarters · filed 2015-02-24 | $1.15B derived: sum of 3 quarters · filed 2015-02-24 | $1.22B 10-K · filed 2015-02-24 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $0.00 derived: sum of 2 quarters · filed 2012-11-09 | $73.00M 10-Q · filed 2012-11-09 | $3.31B derived: sum of 4 quarters · filed 2014-02-21 | |
| 2012-07-01 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $73.00M 10-Q · filed 2012-08-02 | $3.31B derived: sum of 3 quarters · filed 2014-02-21 | $3.31B derived: sum of 4 quarters · filed 2014-02-21 | |
| 2012-04-01 | $73.00M 10-Q · filed 2012-05-07 | $3.31B derived: sum of 2 quarters · filed 2014-02-21 | $3.31B derived: sum of 3 quarters · filed 2014-02-21 | $3.31B derived: sum of 4 quarters · filed 2014-02-21 | |
| 2012-01-01 | $3.24B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | $3.24B derived: sum of 2 quarters · filed 2014-02-21 | $3.24B derived: sum of 3 quarters · filed 2014-02-21 | $3.31B 10-K · filed 2014-02-21 | $73.00M 10-K · filed 2012-02-23 |
| 2011-10-02 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $0.00 derived: sum of 2 quarters · filed 2011-11-08 | $73.00M 10-Q · filed 2011-11-08 | ||
| 2011-07-03 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $73.00M 10-Q · filed 2011-08-09 | |||
| 2011-04-03 | $73.00M 10-Q · filed 2011-05-10 | ||||
| 2011-01-02 | -$966.00M 10-K · filed 2011-02-25 | ||||
| 2010-01-03 | -$386.00M 10-K · filed 2011-02-25 | ||||
| 2008-12-28 | -$379.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |